Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Viking Therapeutics, Inc.VKTX · Entity 4067 | Chief Development Officer | January 03, 2019 | January 03, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Viking Therapeutics, Inc.
Report date January 03, 2019 · Filed January 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.00001 per shareSEC Table I · non-derivative | Direct | 141,063 |
Reported balance
After 2019-01-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-01-03 · Grant · Acquired 22,667 · Balance 141,063 F1: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. 25% of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. F2: Includes 7,199 shares acquired on November 20, 2018 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.58 · Expires 2029-01-03 | Direct | 66,000 |
Reported balance
After 2019-01-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-01-03 · Grant · Acquired 66,000 · Balance 66,000 F3: 25% of the shares subject to the option will vest on each anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. 25% of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award.
F2: Includes 7,199 shares acquired on November 20, 2018 pursuant to the Issuer's 2014 Employee Stock Purchase Plan.
F3: 25% of the shares subject to the option will vest on each anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2019 Filed Jan 3, 2019 20:33 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 66,000 | $0.00 Strike: $7.58 | $0.00 |
DisclosureSEC source: 0001209191-19-001571 · doc4.xml · derivative · entry 2 Masamune Hiroko · CIK 0001745341 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,000 Underlying: Common Stock · 66,000 shares Expires 2029-01-03 F3 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| January 03, 2019 Filed Jan 3, 2019 20:33 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 22,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-001571 · doc4.xml · nonDerivative · entry 1 Masamune Hiroko · CIK 0001745341 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,063 F1 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. 25% of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. F2 · balance_after: Includes 7,199 shares acquired on November 20, 2018 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| July 01, 2018 Filed Jul 3, 2018 17:25 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 42,000 | $0.00 Strike: $9.49 | $0.00 |
DisclosureSEC source: 0001209191-18-041236 · doc4.xml · derivative · entry 2 Masamune Hiroko · CIK 0001745341 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2028-07-01 F2 · derivative.exercise_date: One-third of the shares subject to the option will vest on each one year anniversary of the grant date. Read SEC document |
| July 01, 2018 Filed Jul 3, 2018 17:25 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-041236 · doc4.xml · nonDerivative · entry 1 Masamune Hiroko · CIK 0001745341 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,197 F1 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.